Back to News
research

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Pfizer CEO Albert Bourla highlighted unexpected competence from Medicare negotiators during 2026 drug pricing talks, praising their business-like pragmatism and problem-solving skills. Bourla called the negotiations a strategic success, noting Pfizer’s deal was the first of 17 companies to follow, signaling market validation and industry-wide adoption. The discussions took place at the White House, where Bourla became the first pharma executive to sign a pricing agreement under the Trump administration’s Medicare reforms. He emphasized the deal’s positive market reception, framing it as a win for Pfizer’s long-term strategy amid evolving healthcare policy pressures. The remarks were made at TD Cowen’s 46th Annual Healthcare Conference, underscoring Pfizer’s proactive engagement in shaping drug pricing policy.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (28).png
Quantum News · Media Library

SA Transcripts158.74K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Pfizer Inc. (PFE) TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM EST Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Steve Scala - TD Cowen, Research Division Presentation Steve ScalaTD Cowen, Research Division Well, good morning once again, and welcome to TD Cowen's 46th Annual Healthcare Conference. We're delighted to have you here. We're especially delighted to welcome Pfizer back to the conference this year and representing the company, Albert Bourla, who is Chairman and CEO. So Albert, thank you so much for making the journey. Albert BourlaChairman of the Board & CEO Great pleasure. Question-and-Answer Session Steve ScalaTD Cowen, Research Division Lots to talk about, so much going on internally to Pfizer, but also in the external environment. So I'd like to start out with the external environment. Albert, you were front and center through the whole process of negotiating deals with President Trump. You were the first person to be in the White House to sign the deal. What surprised you most about that process and the outcome for Pfizer relative to the deal? Albert BourlaChairman of the Board & CEO What surprised me the most, it is the competence of the people on the other side of the table, which I didn't expect. Those are people from Medicare, basically, and under all this department, and they were like talking to a business partner. They knew their stuff. They were very pragmatic. They could find solutions. And usually you expect from government negotiators to be the opposite of that. So I think that was very, very surprising. Eventually, I think we did absolutely the right thing, and that was rewarded by the market and that, of course, 16 other companies followed and now there are 17 companies. I think

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.